Probucol
- Generic Name
- Probucol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H48O2S2
- CAS Number
- 23288-49-5
- Unique Ingredient Identifier
- P3CTH044XJ
- Background
A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
- Indication
Used to lower LDL and HDL cholesterol.
- Associated Conditions
- -
- Associated Therapies
- -
Pharmacokinetics Study for Probucol
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01000467
- Locations
- 🇰🇷
Seoul national univeristy, Seoul, Korea, Republic of
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
Phase 4
Completed
- Conditions
- Type 2 Diabetes MellitusArteriosclerosis Obliterans
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2010-04-22
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT00823849
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
Not Applicable
- Conditions
- Type 2 Diabetes MellitusNephropathy
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT00655330
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Safety and Pharmacokinetics of Probucol and Cilostazol
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT00549978
- Locations
- 🇰🇷
Clinical Trial Center, Seoul National University Hospital, Seoul, Korea, Republic of
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
Phase 4
Completed
- Conditions
- GlomerulonephritisIGA Nephropathy
- Interventions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00426348
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath